Healthcare organizations are working on a number of different types of treatments for COVID-19, repurposing old drugs, as well as developing new ones. However, the Food and Drug Administration (FDA) confirmed that it's working on developing a new type of treatment using the blood of patients who have successfully recovered from the virus.

FDA Commissioner Stephen Hahn said during a White House press briefing that the agency has been experimenting with the possibility of using donated blood plasma from recovered patients to develop a treatment. These antibodies, which are introduced into a patient once the platelets and cells have been filtered out, can boost said patient's immune system and help fight against a pathogen as a short-term treatment.

A nurse taking a blood donation from a donor.

Image source: Getty Images.

Hahn went on to say that his agency would keep in touch with regards to this type of treatment. Should it prove to be a success, which seems quite possible, it would provide COVID-19 patients with a short-term treatment that can help manage symptoms until an alternative is developed.

Further details

Biotech companies in the private sector have announced their own blood-based COVID-19 treatment candidates, as well. Takeda Pharmaceuticals (NYSE:TAK) announced earlier in March that the company is testing a plasma-derived therapy in patients who are at high risk of dying from the virus.

Emergent BioSolutions (NYSE:EBS) also announced two new potential COVID-19 treatments that are also based on human plasma antibodies. The company has already started collection efforts and expects to start clinical trials in Q3 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.